Johnson and Johnson Recalls Blood Glucose Meters After Death (JNJ)

Johnson and Johnson Recalls Blood Glucose Meters After Death (JNJ)


Healthcare product company, Johnson & Johnson (JNJ) issues recall on blood glucose meters following the death of a patient.

Following the death of a patient in Europe, JNJ is recalling 1.9 million of its blood glucose meters, including 90,000 in the U.S.

The company is recalling three of its models, which accounts for 1.9 million blood glucose meters in total, including the OneTouch VerioIQ which is sold in the U.S. These devices reportedly gave patients inaccurate reading or shut off when the patient had dangerously high blood sugar levels.

JNJ said that it had started to test this product last year after an internal company noticed that there may be a problem. The error was caused by a software problem.

Johnson & Johnson shares were mostly flat during premarket trading Tuesday. The stock has increased 23% in the past year.

The Bottom Line
Shares of Johnson & Johnson (JNJ) have a 3.06% yield, based on Monday’s closing price of $79.68.

Johnson & Johnson (JNJ) is a “Recommended” dividend stock at this time, holding a DARS™ Rating of 3.5 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Free Updates

Join over 100,000 investors who get the latest news from

Best Dividend Stocks

Looking for stocks that are poised for growth and pay solid dividends? Visit our list of the:

Best Dividend Stocks

Partner Center

Best CD Rates

Sitting on some extra cash and looking for the most current and profitable CD Rates?

Get The Best CD Rates

14 Day Free Trial

Earn more from your dividend portfolio within the next 14 days.

Sign Up Today